Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,accountsPayable,deferredLongTermLiab,longTermInvestments,inventory,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,quoteSourceName,triggerable,marketState,currency,regularMarketPreviousClose,bid,ask,bidSize,askSize,fullExchangeName,financialCurrency,regularMarketOpen,averageDailyVolume3Month,averageDailyVolume10Day,exchange,longName,messageBoardId,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,market,esgPopulated,regularMarketChange,regularMarketChangePercent,regularMarketTime,regularMarketPrice,regularMarketDayHigh,regularMarketDayRange,regularMarketDayLow,regularMarketVolume,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,shortName,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeDataDelayedBy,tradeable,firstTradeDateMilliseconds,priceHint,displayName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,GLPGF,2600401000.0,54299100,,,-64959000,,-64329000,60954000,14204000,-46750000,-46750000,,-8140000,,,,-630000,153070000,199820000,138866000,-18209000,,-64329000,-64329000,63072000.0,2729824000.0,2767144000.0,2663473000.0,418784000.0,5430617000.0,291912000.0,9286000.0,-345101000.0,2168730000.0,-13162000.0,126151000.0,2642639000.0,576985000.0,4451000.0,-13162000.0,111900000.0,5129494000.0,2363969000.0,113600000.0,151721000.0,,,,193521000.0,-159709000.0,182194000.0,-2277000.0,-1952000.0,11910000.0,325000.0,88689000.0,-9629000.0,-81922000.0,15977000.0,3000.0,-1119000.0,75158000.0,40190000.0,-10926000.0,,4552509000.0,en-US,US,EQUITY,Delayed Quote,False,PREPRE,USD,56.8,0.0,0.0,0,0,Other OTC,EUR,58.75,6467,2871,PNK,Galapagos NV,finmb_1716658,America/New_York,EDT,-14400000,us_market,False,1.9500008,3.4331002,1630524767,58.75,58.75,58.75 - 58.75,58.75,16,7.75,0.15196079,51.0 - 143.0,-84.25,-0.58916086,51.0,143.0,-3.516,GALAPAGOS NV,40.65,58.713715,0.0362854,0.0006180055,72.88246,-14.132462,-0.19390757,3225592320,1.4452643,15,0,False,1249306200000,2,Galapagos,0.34,-54.92%,30.90%,143.00,51.00,58.71,72.88,6.47k,2.87k,54.3M,,43.18M,26.23%,31.20%,,,,,,,,,,,,,,,,"Dec 30, 2020","Jun 29, 2021",-32.99%,-24.02%,-1.57%,-8.05%,590.28M,9.03,34.70%,6.59M,-121.84M,-218.92M,-3.52,,5.01B,76.41,27.91M,1.05,8.89,40.65,-420.64M,-176.71M,Value,2800,,1397,8,7,"Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, SjÃ¶gren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.Ã  r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.",Mechelen,32 1 534 29 00,1,1609372800,1625097600,6,Belgium,http://www.glpg.com,86400,6,Generaal De Wittelaan L11 A3,32 1 534 29 01,
t-1,GLPGF,2635724000.0,54299100,,,-12673000,,9361000,44996000,-5802000,-50798000,-50798000,,-4845000,,,,157000,124158000,174956000,129960000,38125000,22191000.0,-12830000,9361000,65738000.0,2729558000.0,2913597000.0,2701462000.0,437020000.0,5615059000.0,291852000.0,15882000.0,-306881000.0,2286059000.0,-13067000.0,127105000.0,2553950000.0,605362000.0,4440000.0,-13067000.0,111294000.0,5310922000.0,2560743000.0,180347000.0,161867000.0,,,,479889000.0,-113164000.0,499859000.0,-1780000.0,478000.0,-11910000.0,2258000.0,410879000.0,31750000.0,-121209000.0,5019000.0,5000.0,-300000.0,31883000.0,-42098000.0,-8488000.0,,4705560000.0,en-US,US,EQUITY,Delayed Quote,False,PREPRE,USD,56.8,0.0,0.0,0,0,Other OTC,EUR,58.75,6467,2871,PNK,Galapagos NV,finmb_1716658,America/New_York,EDT,-14400000,us_market,False,1.9500008,3.4331002,1630524767,58.75,58.75,58.75 - 58.75,58.75,16,7.75,0.15196079,51.0 - 143.0,-84.25,-0.58916086,51.0,143.0,-3.516,GALAPAGOS NV,40.65,58.713715,0.0362854,0.0006180055,72.88246,-14.132462,-0.19390757,3225592320,1.4452643,15,0,False,1249306200000,2,Galapagos,0.34,-54.92%,30.90%,143.00,51.00,58.71,72.88,6.47k,2.87k,54.3M,,43.18M,26.23%,31.20%,,,,,,,,,,,,,,,,"Dec 30, 2020","Jun 29, 2021",-32.99%,-24.02%,-1.57%,-8.05%,590.28M,9.03,34.70%,6.59M,-121.84M,-218.92M,-3.52,,5.01B,76.41,27.91M,1.05,8.89,40.65,-420.64M,-176.71M,Value,2800,,1397,8,7,"Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, SjÃ¶gren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.Ã  r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.",Mechelen,32 1 534 29 00,1,1609372800,1625097600,6,Belgium,http://www.glpg.com,86400,6,Generaal De Wittelaan L11 A3,32 1 534 29 01,
t-2,GLPGF,2616124000.0,54299100,,,-12673000,,0,44996000,0,0,-50798000,,-4845000,,,,0,0,0,0,0,22191000.0,-12830000,9361000,54231000.0,2727840000.0,3047375000.0,2670355000.0,456487000.0,5717731000.0,353819000.0,33909000.0,-334701000.0,2389066000.0,-76603000.0,181824000.0,2135187000.0,635274000.0,4475000.0,-76603000.0,103378000.0,5369347000.0,,173399000.0,171316000.0,13334000.0,8951000.0,355000.0,479889000.0,0.0,499859000.0,-1780000.0,478000.0,-11910000.0,2258000.0,410879000.0,31750000.0,-121209000.0,5019000.0,5000.0,-300000.0,31883000.0,-42098000.0,-8488000.0,,4734073000.0,en-US,US,EQUITY,Delayed Quote,False,PREPRE,USD,56.8,0.0,0.0,0,0,Other OTC,EUR,58.75,6467,2871,PNK,Galapagos NV,finmb_1716658,America/New_York,EDT,-14400000,us_market,False,1.9500008,3.4331002,1630524767,58.75,58.75,58.75 - 58.75,58.75,16,7.75,0.15196079,51.0 - 143.0,-84.25,-0.58916086,51.0,143.0,-3.516,GALAPAGOS NV,40.65,58.713715,0.0362854,0.0006180055,72.88246,-14.132462,-0.19390757,3225592320,1.4452643,15,0,False,1249306200000,2,Galapagos,0.34,-54.92%,30.90%,143.00,51.00,58.71,72.88,6.47k,2.87k,54.3M,,43.18M,26.23%,31.20%,,,,,,,,,,,,,,,,"Dec 30, 2020","Jun 29, 2021",-32.99%,-24.02%,-1.57%,-8.05%,590.28M,9.03,34.70%,6.59M,-121.84M,-218.92M,-3.52,,5.01B,76.41,27.91M,1.05,8.89,40.65,-420.64M,-176.71M,Value,2800,,1397,8,7,"Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, SjÃ¶gren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.Ã  r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.",Mechelen,32 1 534 29 00,1,1609372800,1625097600,6,Belgium,http://www.glpg.com,86400,6,Generaal De Wittelaan L11 A3,32 1 534 29 01,
t-3,GLPGF,2670968000.0,54299100,,,-81518000,,-81905000,44115000,11760000,-32355000,-32355000,,-61994000,,,,387000,144017000,176372000,132257000,-49163000,22191000.0,-81905000,-81905000,41114000.0,2725608000.0,3009004000.0,2712082000.0,437369000.0,5721086000.0,290929000.0,15868000.0,-297098000.0,2385310000.0,-7357000.0,121542000.0,2087797000.0,601744000.0,3856000.0,-7357000.0,94661000.0,5463769000.0,3220805000.0,139299000.0,157259000.0,,,,-60691000.0,-75061000.0,-81084000.0,-2050000.0,353000.0,11571000.0,2404000.0,-296424000.0,-35351000.0,-180340000.0,4229000.0,187000.0,-37000.0,-108009000.0,68872000.0,-16045000.0,-1000.0,4862025000.0,en-US,US,EQUITY,Delayed Quote,False,PREPRE,USD,56.8,0.0,0.0,0,0,Other OTC,EUR,58.75,6467,2871,PNK,Galapagos NV,finmb_1716658,America/New_York,EDT,-14400000,us_market,False,1.9500008,3.4331002,1630524767,58.75,58.75,58.75 - 58.75,58.75,16,7.75,0.15196079,51.0 - 143.0,-84.25,-0.58916086,51.0,143.0,-3.516,GALAPAGOS NV,40.65,58.713715,0.0362854,0.0006180055,72.88246,-14.132462,-0.19390757,3225592320,1.4452643,15,0,False,1249306200000,2,Galapagos,0.34,-54.92%,30.90%,143.00,51.00,58.71,72.88,6.47k,2.87k,54.3M,,43.18M,26.23%,31.20%,,,,,,,,,,,,,,,,"Dec 30, 2020","Jun 29, 2021",-32.99%,-24.02%,-1.57%,-8.05%,590.28M,9.03,34.70%,6.59M,-121.84M,-218.92M,-3.52,,5.01B,76.41,27.91M,1.05,8.89,40.65,-420.64M,-176.71M,Value,2800,,1397,8,7,"Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, SjÃ¶gren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.Ã  r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.",Mechelen,32 1 534 29 00,1,1609372800,1625097600,6,Belgium,http://www.glpg.com,86400,6,Generaal De Wittelaan L11 A3,32 1 534 29 01,
